Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 2/20 | 0.65 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.65 |
| ▸ | HTR7 | P34969 | 4/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.58 |
| ▸ | BCHE | P06276 | 2/20 | 0.56 |
| ▸ | ACHE | P22303 | 2/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 2/20 | 0.54 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21908927 | 0.94 | LTA4H (0.62) | KDM4AKDM4CHTR7SIGMAR1LTA4H | |
| SCHEMBL5522971 | 0.88 | MEN1 (0.56) | KDM4AKDM4CSIGMAR1ACHELTA4H | |
| SCHEMBL1005793 | 0.87 | SIGMAR1 (0.62) | KDM4AKDM4CSIGMAR1LTA4HTMEM97 | |
| SCHEMBL25203501 | 0.87 | HDAC1 (0.62) | KDM4AKDM4CBCHEACHELTA4H | |
| SCHEMBL16730590 | 0.87 | HDAC1 (0.62) | KDM4AKDM4CBCHEACHELTA4H | |
| SCHEMBL25415046 | 0.86 | KDM4A (0.62) | KDM4AKDM4CHTR7SIGMAR1BCHE | |
| SCHEMBL25121045 | 0.86 | BCHE (0.74) | KDM4AKDM4CSIGMAR1BCHEACHE | |
| SCHEMBL380668 | 0.86 | KDM4A (0.62) | KDM4AKDM4CHTR7SIGMAR1BCHE | |
| SCHEMBL7205122 | 0.84 | KDM4A (0.76) | KDM4AKDM4CHTR7SIGMAR1ACHE | |
| SCHEMBL8904225 | 0.83 | KDM4A (0.56) | KDM4AKDM4CHTR7SIGMAR1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200030325-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | ACETYLON PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20170305866-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | THE GENERAL HOSPITAL CORPORATION | 2017-10-26 | — | — | US | disclosed |
| US-20170305866-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | THE GENERAL HOSPITAL CORPORATION | 2017-10-26 | — | — | US | disclosed |
| US-20160375021-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS, INC. | 2016-12-29 | — | — | US | disclosed |
| US-9512083-B2 | Histone deacetylase 6 selective inhibitors for the treatment of bone disease | THE GENERAL HOSPITAL CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512083-B2 | Histone deacetylase 6 selective inhibitors for the treatment of bone disease | THE GENERAL HOSPITAL CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| EP-3091004-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | Acetylon Pharmaceuticals, Inc. (US) | 2016-11-09 | — | — | EP | disclosed |
| EP-2526093-B1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS INC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20150045380-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS | 2015-02-12 | — | — | US | disclosed |
| US-20150045380-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS | 2015-02-12 | — | — | US | disclosed |
| WO-2013013113-A2 | HISTONE DEACETYLASE 6 SELECTIVE INHIBITORS FOR THE TREATMENT OF BONE DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20120190693-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | ACETYLON PHARMACEUTICALS, INC. | 2012-07-26 | — | — | US | disclosed |
| US-20120190693-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | ACETYLON PHARMACEUTICALS, INC. | 2012-07-26 | — | — | US | disclosed |
| US-20120083504-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | ACETYLON PHARMACEUTICALS, INC. | 2012-04-05 | — | — | US | disclosed |
| US-20120083504-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | ACETYLON PHARMACEUTICALS, INC. | 2012-04-05 | — | — | US | disclosed |
| US-8148526-B1 | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | ACETYLON PHARMACEUTICALS (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148526-B1 | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | ACETYLON PHARMACEUTICALS (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110300134-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110300134-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2011091213-A2 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300134-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC3 | KDM4A 1045/4885KDM4C 2025/4885HTR7 4586/4885 |
| US-20160375021-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC3 | KDM4A 1045/4885KDM4C 2025/4885HTR7 4586/4885 |
| US-20150045380-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC3 | KDM4A 1045/4885KDM4C 2025/4885HTR7 4586/4885 |
| US-20200030325-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | HDAC6, HDAC1, HDAC3 | KDM4A 1045/4885KDM4C 2025/4885HTR7 4586/4885 |
| US-20170305866-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | HDAC1, HDAC6, HDAC9 | KDM4A 183/4885KDM4C 412/4885HTR7 4241/4885 |
| US-20120190693-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | HDAC6, HDAC1, HDAC3 | KDM4A 1045/4885KDM4C 2025/4885HTR7 4586/4885 |
| US-20120083504-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | HDAC6, HDAC1, HDAC3 | KDM4A 1045/4885KDM4C 2025/4885HTR7 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.